



RUSSIAN
SOCIETY
OF CARDIOLOGY

V GLOBAL EDUCATIONAL FORUM

«RUSSIAN CARDIOVASCULAR DAYS»

2 EUROPE SQ., MOSCOW
(RADISSON SLAVYANSKAYA HOTEL BUSINESS CENTRE)

MARCH 30 – APRIL 1, 2017

www.scardio.ru

V GLOBAL EDUCATIONAL FORUM

MARCH 30 – APRIL 1, 2017 | MOSCOW

DEAR COLLEAGUES!

We are delighted to welcome the delegates of the V Global Educational Forum “Russian Cardiovascular Days”.

Interactive scientific programme of the Forum includes clinical case discussions, lectures, symposia and master classes dedicated to the hot issues of cardiology and refers to the latest European guidelines. Leading Russian and European experts will discuss the most pressing problems and answer questions of interest from the audience.

Within the Forum different aspects of diagnosis and therapy of hypertension, acute coronary syndrome, arrhythmias, heart failure and pulmonary hypertension will be discussed. We believe the programme will be exiting and challenging for a wide range of practicing specialists and students of cardiology and internal medicine.

Welcome to Moscow!

Scientific Committee Co-chairmen:



Professor
M. Komajda (France)



Professor
E. Shlyakhto (Russia)

V GLOBAL EDUCATIONAL FORUM

MARCH 30 – APRIL 1, 2017 | MOSCOW

GENERAL INFORMATION

The Forum will be open from March 30th to April 1st 2017
in Radisson Slavyanskaya Hotel and Business Centre (2 Europe Square),
Kievskaya Metro Station. Entrance on the side of the Trade Centre.



**THURSDAY,
MARCH 30**

08:30–17:00 Registration
09:00–18:15 Exhibition
09:15–16:30 Scientific symposia
17:00–18:15 Opening Ceremony
18.15–19.30 Poster session
18:15–19:30 Reception



**FRIDAY,
MARCH 31**

08:00–17:00 Registration
08:30–18:10 Exhibition
09:00–18:10 Plenary sessions
13:00–14:00 Coffee break



**SATURDAY,
APRIL 1**

08:45–14:00 Registration
09:00–15:15 Exhibition
09:30–15:15 Plenary sessions
12:30–13:30 Coffee break
15:15–16:00 CME certificates distribution



V GLOBAL EDUCATIONAL FORUM

MARCH 30 – APRIL 1, 2017 | MOSCOW

GENERAL INFORMATION

Registration

Admission to the scientific symposia and exhibition is free after registration. Registration is obligatory for all participants. Each participant receives a name badge, which allows to enter all scientific symposia and exhibition.

Printed materials

Each participant can purchase a bag with all congress materials including printed scientific programme and abstract book. The congress bag price is 1,500 RUR (for RSC members – 1,000 RUR).

RSC Board members, session chairmen, speakers, the young scientists – travel grants receivers are provided with all printed materials free of charge.

Information for speakers

Presentation slides should be given to PC-operators in the meeting hall on electronic media (stickers, CDs) 30 minutes prior to a session.

Exhibition

Exhibition of medications, medical equipment and medical literature will be held daily in the lobby of the 2nd floor (entrance on the side of the Trade Centre).

Posters

Poster session will be held in the lobby of the 2nd floor on March 30th from 18:15 till 19:30.

Simultaneous translation

Simultaneous translation will be provided during the Opening Ceremony and all plenary sessions.



V GLOBAL EDUCATIONAL FORUM

MARCH 30 – APRIL 1, 2017 | MOSCOW


GENERAL INFORMATION

European CME credits (ECMEC)

V Global Educational Forum «Russian Cardiovascular Days» was granted 13 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). To receive the certificate, please register on the first Congress day, March 30, before 5.00 pm and announce your wish to receive a CME Certificate. On the last Congress day, April 1, before 4.00 pm you can get the individually numbered certificate in the registration area.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.


ПЛАН ПЕРВОГО ЭТАЖА
PLAN OF THE FIRST FLOOR



V GLOBAL EDUCATIONAL FORUM

MARCH 30 – APRIL 1, 2017 | MOSCOW

PLAN OF HALLS



PROGRAMME



THURSDAY, MARCH 30
CONFERENCE HALL

17:00

Welcome remarks
M. Komajda (France)
E. Shlyakhto (Russia)

17:15–17:45

Opening lecture
Neuro-modulation in cardiology
F. Mahfoud (Germany)

17:45–18:15

Opening lecture
Translational research and progress in cardiology
E. Shlyakhto (Russia)

18:15–19:30

Poster session
Moderators:
A. Konradi (Russia)
A. Nedoshivin (Russia)
O. Bolshakova (Russia)



PROGRAMME




FRIDAY, MARCH 31
CONFERENCE HALL

HIGHLIGHTS OF THE ESC CONGRESS 2016 IN ROME

09:00–09:30	Arrhythmias R. Frank (France)
09:30–09:50	Commentary A. Revishvili (Russia)
09:50–10:20	Acute coronary syndrome/interventional cardiology M. Roffi (Switzerland)
10:20–10:50	Commentary O. Barbarash (Russia)
10:50–11:20	Break
11:20–11:50	Heart Failure M. Komajda (France)
11:50–12:10	Commentary G. Arutyunov (Russia)
12:10–12:40	Prevention of CVD M. Komajda (France)
12:40–13:00	Commentary A. Konradi (Russia)
13:00–14:00	Break

PROGRAMME




FRIDAY, MARCH 31
CONFERENCE HALL

NEW ESC GUIDELINES

- | | |
|-------------|---|
| 14:00–14:20 | Patient with atrial fibrillation: clinical case
A. Revishvili (Russia) |
| 14:20–14:50 | What do ESC Guidelines say?
R. Frank (France) |
| 14:50–15:20 | Patient with heart failure: clinical case
G. Arutyunov (Russia) |
| 15:20–15:40 | What do ESC Guidelines say?
M. Komajda (France) |
| 15:40–16:00 | Cardiac Complications in Oncology: clinical case
G. Gendlin (Russia) |
| 16:00–16:30 | What do ESC Guidelines say?
T. Gillebert (Belgium) |
| 16:30–16:50 | Patient with pulmonary hypertension: clinical case
O. Moiseeva (Russia) |
| 16:50–17:20 | What do ESC Guidelines say?
T. Gillebert (Belgium) |
| 17:20–17:50 | Inflammatory disease of the heart
J. Lehtonen (Finland) |
| 17:50–18:10 | Discussion
G. Gendlin (Russia) |



PROGRAMME



SATURDAY, APRIL 1
CONFERENCE HALL

HOT TOPICS IN CARDIOLOGY

- | | |
|-------------|---|
| 09:30–10:00 | Telemonitoring in heart failure: Does it work?
M. Cowie (UK) |
| 10:00–10:20 | Discussion
S. Matskeplishvili (Russia) |
| 10:20–10:50 | How low should we lower blood pressure?
S. Kjeldsen (Norway) |
| 10:50–11:10 | Discussion
E. Baranova (Russia) |
| 11:10–11:40 | Break |
| 11:40–12:10 | Lipid-lowering therapy: state-of-the art
M. Ezhov (Russia) |
| 12:10–12:30 | Discussion
Panel discussion |
| 12:30–13:30 | Break |
| 13:30–14:00 | Cardiac amyloidosis: the Russian point of view
A. Gudkova (Russia) |
| 14:00–14:30 | Cardiac amyloidosis: the international point of view
T. Damy (France) |
| 14:30–15:00 | Closing lecture
Implementation of outcome-based medicine
concept in cardiology
A. Nedoshivin (Russia) |
| 15:00–15:15 | Closing remarks
M. Komajda (France)
A. Nedoshivin (Russia) |

SCIENTIFIC SYMPOSIA

THURSDAY, MARCH 30

THURSDAY, MARCH 30 SCIENTIFIC SYMPOSIA

	Conference Hall	Tolstoy Hall
09:15–10:45	Symposium Damage of brain as a target organ in AH patients: current approaches to diagnosis (RSC section of cardioneurology)	Symposium Prolongation of dual antiplatelet therapy beyond 1 year in patients after myocardial infarction (supported by AstraZeneca)
10:45–11:15	Break	
11:15–12:45	Symposium Hot issues in ACS treatment (supported by Sanofi) On-line broadcasting	Symposium Current aspects of antianginal therapy in clinical practice (supported by Berlin-Chemie)
12:45–13:15	Break	
13:15–14:45	Symposium Evolocumab: victory in the fight against cardiovascular diseases. Innovative biotechnology in cardiology (supported by Amgen)	Symposium Five years of NOAC experience in practice of cardiologists and general physicians. Have we improved the treatment of patients with atrial fibrillation? (supported by Bayer) On-line broadcasting
14:45–15:00	Break	
15:00–16:30	Symposium From dusk till dawn: life after ACS (supported by AstraZeneca) On-line broadcasting	Master class Management of pulmonary embolism based on risk stratification
16:30–17:00	Break	
17:00–18:15	OPENING CEREMONY On-line broadcasting Simultaneous translation	X
18:15–19:30	Poster session Welcome reception	



SCIENTIFIC SYMPOSIA

THURSDAY, MARCH 30

09:15–10:45
Conference Hall

Symposium

**Damage of brain as a target organ in AH patients:
current approaches to diagnosis
(RSC Section of cardioneurology)**

Chairpersons:

Ostroumova O.D. (Moscow), Zueva I.B. (Saint-Petersburg)

Ostroumova O.D. (Moscow). Brain as a target organ in arterial hypertension. Methods of cognitive function assessment in AH patients.

Zueva I.B. (Saint-Petersburg). Cognitive evoked potentials method in brain function assessment in patients with AH and metabolic syndrome.

Karavashkina E.A. (Moscow). Complex approach to cognitive disorders management in AH patients.

Perepelova E.M., Perepelov B.A. (Moscow). New MRI methods in diagnostics of damage of brain as a target organ in AH patients.

09:15–10:45
Tolstoy Hall

Symposium

**Prolongation of dual antiplatelet therapy beyond 1 year
in patients after myocardial infarction
(supported by AstraZeneca)**

Chairperson: Ruda M.Ya. (Moscow)

Panchenko E.P. (Moscow). High risks of cardiovascular events a year after myocardial infarction.

Yavelov I.S. (Moscow). General results of the PEGASUS study.

Averkov O.V. (Moscow). Brilinta 60 mg – whom could it be prescribed to?

10:45–11:15

Break



SCIENTIFIC SYMPOSIA

THURSDAY, MARCH 30

11:15–12:45
Conference Hall

Symposium
Hot issues in ACS treatment
(supported by Sanofi)
On-line broadcasting

Chairperson: Shlyakhto E.V. (Saint-Petersburg)

Yavelov I.S. (Moscow). Dual antiplatelet therapy in ACS patients: current approaches, controversial issues.

Yakovlev A.N. (Saint-Petersburg). Duration of and adherence to dual antiplatelet therapy in ACS patients: benefits and limitations.

Averkov O.V. (Moscow). Difficult ACS cases.

11:15–12:45
Tolstoy Hall

Symposium
Current aspects of antianginal therapy in clinical practice
(supported by Berlin-Chemie)

Chairpersons:

Nedoshivin A.O. (Saint-Petersburg),
Karpov Yu.A. (Moscow), Vasyuk Yu.A. (Moscow)

Karpov Yu.A. (Moscow). Combined antianginal therapy today.

Nedoshivin A.O. (Saint-Petersburg). Life quality indicators in clinical practice. Impact of a doctor?

Vasyuk Yu. A. (Moscow). Effectiveness of antianginal therapy in different clinical situations.

12:45–13:15

Break



SCIENTIFIC SYMPOSIA

THURSDAY, MARCH 30

13:15–14:45
Conference Hall

Symposium

Evolocumab: victory in the fight against cardiovascular diseases. Innovative biotechnologies in cardiology (supported by Amgen)

Chairpersons: Barbarash O.L. (Kemerovo), Karpov Y.A. (Moscow), Ezhov M.V. (Moscow)

Barbarash O.L. (Kemerovo), Karpov Y.A., Ezhov M.V. (Moscow). Welcome and introduction.

Barbarash O.L. (Kemerovo), Karpov Y.A., Ezhov M.V. (Moscow). Unsolved problem of atherosclerosis.

Bubnova M.G. (Moscow) Evolocumab: the revolution in lowering LDL-C and other atherogenic lipids.

Karpov Y.A. (Moscow). Evolocumab: the first PCSK9 inhibitor showing plaque regression.

Ezhov M.V. (Moscow). Evolocumab: unprecedented results of FOURIER study in the impact on cardiovascular events.

Panel discussion.

Moderator – Gurevich V.S. (Saint-Petersburg).

Barbarash O.L. (Kemerovo), Karpov Y.A., Ezhov M.V. (Moscow). Closing remarks.

13:15–14:45
Tolstoy Hall

Symposium

Five years of NOAC experience in practice of cardiologists and general physicians. Have we improved the treatment of patients with atrial fibrillation? (supported by Bayer)

On-line broadcasting

Chairperson: Arutunov G.P. (Moscow)

Arutunov G.P. (Moscow). Five years of NOAC experience in practice of cardiologists and general physicians. Have we improved the treatment of patients with atrial fibrillation?



SCIENTIFIC SYMPOSIA

THURSDAY, MARCH 30

Andreev D.A. (Moscow). PIONEER AF-PCI: results of the first open-label randomized controlled multi-center study exploring two treatment strategies of Rivaroxaban in comparison with the dose-adjusted oral vitamin K antagonist treatment strategy in patients with atrial fibrillation after PCI.

Glezer M.G. (Moscow). Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease. What can we do better?

14:45–15:00

Break

15:00–16:30

Conference Hall

Symposium

**From dusk till dawn: life after ACS
(supported by AstraZeneca)**

On-line broadcasting

Chairperson: Matskeplishvili S.T. (Moscow)

Lebedeva A.Yu. (Moscow). Acute coronary syndrome: so that the evening was not the last one (clinical case).

Gilyarov M.Yu. (Moscow). At night all cats are grey. What antiplatelet to choose for a patient for the 1st year after myocardial infarction?

Matskeplishvili S.T (Moscow). Towards dawn – PEGASUS study results.

15:00–16:30

Tolstoy Hall

Master class

Management of pulmonary embolism based on risk stratification

Moderators:

Duplyakov D.V. (Samara), Khasanov N.R. (Kazan')

PARTNERS

General partner



Partners



Science For A
Better Life



**БЕРЛИН-ХЕМИ
МЕНАРИНИ**



General media partner



ИНТЕРНЕТ СЕССИЯ
ВСЕРОССИЙСКАЯ ОБРАЗОВАТЕЛЬНАЯ ПРОГРАММА ДЛЯ ВРАЧЕЙ

Media partners



**ИЗДАТЕЛЬСКАЯ ГРУППА
«ГЭОТАР-Медиа»**

КАРДИОЛОГИЯ



**РОССИЙСКИЙ
КАРДИОЛОГИЧЕСКИЙ ЖУРНАЛ**
НАУЧНО-ОБРАЗОВАТЕЛЬНЫЙ РЕЦЕПТУРИНГОВЫЙ МЕДИЦИНСКИЙ ЖУРНАЛ
РОССИЙСКОГО КАРДИОЛОГИЧЕСКОГО ОБЩЕСТВА



* Данные, полученные в рандомизированном, двойном слепом, плацебо- и эзетимиб-контролируемом, многоцентровом международном исследовании (LAPLACE-2) с участием 1896 пациентов с семейной гиперлипидемией или смешанной дислипидемией. В среднем медиана 10 и 12 недель лечения 88-95% пациентов, получающих Ревата и статины, достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л)² (средние пациенты, принимающие только статины, 2-39% пациентов достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л)). (Средние пациенты, получающих аторвастатин и эзетимиб, 17-62% пациентов достигли уровня ХС-ЛПНП < 70 мг/дл (< 1,8 ммоль/л)²

[illegible][illegible]

RU-P-145-0616-033178